title: [Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology].
abstract: Prostate cancer, the most frequent cancer in man, is an adenocarcinoma sensible to chemical castration in more than 80% of cases due to its hormonal dependency. Androgen deprivation is the treatment for advanced cancer and can be associated with radiotherapy locally or in locally advanced situations. Multidisciplinary therapeutic choice depends on patient age and co-morbidities and clinical stage. The impact of hormonal treatment confers varied side effects and cardiovascular effects are now better known. Responsible mechanisms of this cardiotoxicity are at the same time direct but also indirect by metabolic thermogenic effects. Analysis of these clinical or biological effects, their correlations to the used type of hormonal treatment and the possible precautions of prescription will be detailed in this analysis of the literature. The collaboration of the oncologist or the urologist with the cardiologist becomes necessary and the existence of a unit of oncocardiology could improve the evaluation of the risk-benefit balance and the tolerance of the treatment.
authors.affiliation: Groupe Oncorad-Garonne, service d'oncologie-radiothérapie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France; Groupe Oncorad-Garonne, unité d'oncocardiologie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France. Electronic address: i.latorzeff@clinique-pasteur.com.
authors.forename: I
authors.initials: I
authors.lastname: Latorzeff
authors.affiliation: Service d'urologie, clinique Saint-Jean-du-Languedoc, 20, route de Revel, 31400 Toulouse, France.
authors.forename: G
authors.initials: G
authors.lastname: Ploussard
authors.affiliation: Service d'urologie, clinique Pasteur, 45, avenue de Lombez, 31300 Toulouse, France.
authors.forename: J
authors.initials: J
authors.lastname: Guillotreau
authors.affiliation: Service d'urologie, clinique Ambroise-Paré, 387, route de Saint-Simon, 31100 Toulouse, France.
authors.forename: F
authors.initials: F
authors.lastname: Jonca
authors.affiliation: Service d'urologie, clinique des Cèdres, château d'Alliez, 31700 Cornebarrieu, France.
authors.forename: P
authors.initials: P
authors.lastname: Labarthe
authors.affiliation: Service d'urologie, clinique d'Occitanie, 20, avenue Bernard-IV, 31600 Muret, France.
authors.forename: G
authors.initials: G
authors.lastname: Rollin
authors.affiliation: Service d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France.
authors.forename: J-B
authors.initials: JB
authors.lastname: Beauval
authors.affiliation: Groupe Oncorad-Garonne, unité d'oncocardiologie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France; Service de cardiologie, clinique Pasteur, 45, avenue de Lombez, 31300 Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Pathak
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects*; D000072096:Cardiologists; D002309:Cardiology; D066126:Cardiotoxicity / Q000209:etiology*; D006801:Humans; D008297:Male; D008495:Medical Oncology; D000072103:Oncologists; D010348:Patient Care Team; D011471:Prostatic Neoplasms / Q000628:therapy*; D018570:Risk Assessment
chemical_list: D000726:Androgen Antagonists
keywords: Cancer de la prostate; Cardiovascular risk; Hormonal treatment; Hormonothérapie; Prostate cancer; Risque cardiovasculaire; Unit of oncocardiology; Unité oncocardiologie